Overview

This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn’s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease.

Full Product Details

Author:   Adam S. Cheifetz ,  Joseph D. Feuerstein
Publisher:   Springer International Publishing AG
Imprint:   Springer International Publishing AG
Edition:   Softcover reprint of the original 1st ed. 2018
Weight:   0.718kg
ISBN:  

9783319868233

ISBN 10:   3319868233
Pages:   335
Publication Date:   05 September 2018
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Paperback
Publisher's Status:   Active
Availability:   Manufactured on demand  
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Mechanism of Action and Pharmacokinetics of Biologics.- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis.- Anti-tumor Necrosis Factor Agents in Crohn’s Disease.- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease.- Use of Biologics in the Postoperative Management of Crohn’s Disease.- Biologics in Pregnancy and Breastfeeding.- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease.- Therapeutic Drug Monitoring of Biologic Agents.- Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks.- Cessation of Biologics – Can it be Done?.- Biologic Therapy in Pediatric Inflammatory Bowel Disease.- Infectious Complications of Biologics.- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy.- Non-infectious and Non-malignant Complications of Biologics.- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances.- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications.- Novel Agents in Inflammatory Bowel Disease.- Quality, Safety, and Practical Considerations of Using Biologic Therapies. 

Reviews

Author Information

Adam S. Cheifetz, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Joseph D. Feuerstein, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions